Preclinical testing of drug-induced proarrhythmia: value of transgenic models

L Fabritz, G Breithardt, P Kirchhof

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Drug-induced proarrhythmia is a serious medical problem that causes relevant morbidity and mortality. It is also a relevant problem for the development of novel pharmacological compounds. Therefore, there is a need for sensitive, specific and high-throughput preclinical tests to detect a risk for drug-induced proarrhythmia early in the development of new drugs. The review focuses on the potential role of transgenic models with altered repolarisation but without overt structural heart disease for drug-induced proarrhythmia screening. Today, selected murine models with alterations in K+, Na+ channels and ankyrin are available. In the future, transgenic rabbit and Zebra fish models may also be used.

Original languageEnglish
Pages (from-to)289-94
Number of pages6
JournalCardiovascular & Hematological Agents in Medicinal Chemistry
Issue number4
Publication statusPublished - Oct 2007


  • Action Potentials
  • Animals
  • Animals, Genetically Modified
  • Anti-Arrhythmia Agents
  • Arrhythmias, Cardiac
  • Disease Models, Animal
  • Drug Design
  • Humans
  • Mice
  • Potassium Channels
  • Sodium Channels


Dive into the research topics of 'Preclinical testing of drug-induced proarrhythmia: value of transgenic models'. Together they form a unique fingerprint.

Cite this